Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $25,260.10 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Iqbal Hussain sold 1,010 shares of the stock in a transaction on Friday, January 30th. The shares were sold at an average price of $25.01, for a total value of $25,260.10. Following the completion of the transaction, the insider owned 104,376 shares of the company’s stock, valued at $2,610,443.76. This trade represents a 0.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $23.54 on Friday. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a market cap of $3.16 billion, a PE ratio of -12.86 and a beta of 1.56. The stock’s 50-day moving average price is $25.22 and its two-hundred day moving average price is $22.62.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CNTA. Campbell & CO Investment Adviser LLC bought a new stake in Centessa Pharmaceuticals in the second quarter worth $218,000. American Century Companies Inc. lifted its position in shares of Centessa Pharmaceuticals by 3.5% in the second quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock worth $14,858,000 after buying an additional 37,954 shares during the last quarter. Federated Hermes Inc. bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter worth about $42,429,000. Bollard Group LLC acquired a new position in shares of Centessa Pharmaceuticals during the 2nd quarter valued at about $1,319,000. Finally, Ensign Peak Advisors Inc raised its stake in shares of Centessa Pharmaceuticals by 27.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 559,744 shares of the company’s stock valued at $7,355,000 after acquiring an additional 121,611 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CNTA. Guggenheim lifted their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. B. Riley increased their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Finally, Truist Financial raised their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.